The belimumab-rituximab combination has utility in SLE, but it comes at an incremental safety cost. May well be worth it in many of our patients, but very understandable that the @US_FDA label gets further clarification #ACR23 @US_FDA session @RheumNow https://t.co/RwF2wbsrQk